Lymphoma patients: which pneumonia shot works best?

NCT ID NCT04460235

Recruiting now Knowledge-focused Sponsor: Poitiers University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 02, 2026 · Last updated Jun 16, 2026 · Updated 5 times

Summary

This study compares two pneumococcal vaccination strategies in 160 adults with lymphoma (a type of blood cancer). One group gets two vaccines (PCV13 then PPV23), the other gets a single newer vaccine (PREVENAR20). The goal is to see which approach triggers a stronger immune response, since chemotherapy can weaken the immune system. Results will help guide future vaccination recommendations for these patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU Bordeaux
TERMINATED

Bordeaux, France
CHU Limoges
RECRUITING

Limoges, France

Contact
CHU Poitiers
RECRUITING

Poitiers, France

Contact
CHU Tours
RECRUITING

Tours, France

Contact
Ch Perigueux
RECRUITING

Périgueux, France

Contact
Chu Angers
RECRUITING

Angers, France

Contact
Chu Nantes
TERMINATED

Nantes, France

Conditions

Explore the condition pages connected to this study.

LYMPHOMA, NON-HODGKIN STREPTOCOCCUS PNEUMONIAE VACCINE VACCINE

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

LYMPHOMA